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Context: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human tumors; it is
characterized by chemoresistance, local invasion, and distant metastases. ATC is invariably fatal.
Objective: The aim was to study the role of TWIST1, a basic helix-loop-helix transcription factor,
in ATC.
Design: Expression of TWIST1 was studied by immunohistochemistry and real-time PCR in normal
thyroids and well-differentiated, poorly differentiated, and ATC. The function of TWIST1 was
studied by RNA interference in ATC cells and by ectopic expression in well-differentiated thyroid
carcinoma cells.
Results: ATCs up-regulate TWIST1 with respect to normal thyroids as well as to poorly and well-
differentiated thyroid carcinomas.KnockdownofTWIST1byRNA interference inATCcells reduced
cellmigrationand invasionand increased sensitivity toapoptosis. Theectopic expressionof TWIST1
in thyroid cells induced resistance to apoptosis and increased cell migration and invasion.
Conclusions: TWIST1 plays a key role in determining malignant features of the anaplastic pheno-
type in vitro. (J Clin Endocrinol Metab 96: E772–E781, 2011)
Thyroid neoplasms include a broad spectrum of histo-types, ranging from benign adenomas to differenti-
ated papillary and follicular, poorly differentiated, and
rapidly growing anaplastic carcinomas (1, 2). Papillary
thyroid carcinoma (PTC) far outnumbers the other mor-
phological subtypes and is characterized, in general, by an
indolentphenotypewitha10-yr survival rateofup to90%
(1, 2). Poorly differentiated carcinomas (PDC) include a
heterogeneous group of neoplasms with morphological
features and clinical characteristics intermediate between
those of well-differentiated and anaplastic carcinomas (1,
2). Anaplastic thyroid carcinomas (ATC) represent less
than2%ofall thyroid cancersbut are responsible formore
than 50% of thyroid cancer mortality, with a mean sur-
vival time from diagnosis of 4–12 months (3). ATC is
highly invasive, and themajority of ATCpatients die from
suffocation due to locoregional disease extension or be-
cause of overwhelmingdistantmetastatic disease. Surgical
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treatment, radiotherapy, and chemotherapy, based pri-
marily on doxorubicin and cisplatin, show little efficacy in
ATC patients (3, 4). ATC cells feature a highly mitogenic
and motile phenotype and epithelial-mesenchymal tran-
sitionandare refractory toapoptotic cell death (3, 4).ATC
features genetic lesions that are typical of a well-differen-
tiated carcinoma, namely BRAF or RAS point mutations.
Only a few genetic lesions have been identified exclusively
in ATC, i.e. p53, PI3KCA, or -catenin mutations (5–8).
Therefore, the molecular mechanisms driving the estab-
lishment of the highly aggressive anaplastic phenotype are
still largely unknown (2–5).
We have recently identified, through a cDNAmicroar-
ray analysis, a gene expression signature that is associated
with the highly proliferative and aneuploid ATC pheno-
type (9). Among the genes highly up-regulated in ATC vs.
normal tissue and PTC, we have isolated TWIST1.
TWIST1 is a highly conserved basic helix-loop-helix tran-
scription factor that plays a key role in mesodermal, myo-
blast, and osteoblast differentiation (10, 11). Mutational
inactivation of TWIST1 is responsible for the Saethre-
Chotzen syndrome, an autosomal dominant disorder
characterized by premature fusion of the cranial sutures,
skull deformations, limb abnormalities, and facial dys-
morphism (12). TWIST1 plays an important role in the
development and progression of human cancer. TWIST1
overexpression is reported in many human tumors, in-
cluding rhabdomyosarcoma, glioma, melanoma, breast,
gastric, and prostate carcinomas (13, 14). Elevated
TWIST1 protein levels are associated with advanced tu-
mor stage and poor prognosis in several cancer types (14,
15). TWIST1 promotes epithelial-mesenchymal transition
(16, 17). TWIST1 gene amplification is associated with re-
sistance to chemotherapeutic agents (18, 19). Finally,
TWIST1 inhibits premature senescence in cancer cells (20).
Here we report that TWIST1 plays a key role in the
ATC phenotype in vitro and suggest that it may mediate
chemoresistance of ATC cells.
Materials and Methods
Reagents
Staurosporine and cisplatin were obtained from Sigma-
Aldrich (St. Louis, MO).
Cell cultures
Human cell lines (S11N, P5 4N, 8505C, CAL62, SW1736,
OCUT-2, ACT-1, TPC-1, BCPAP) (21–23), rat cell lines (PC
RET/PTC1, PCRET/PTC3, PC v-HRAS, PC-BRAF-V600E, PC-
TRK-T1, PC v-RAF, PC v-MOS, PC E1A, and PC E1A-v-RAF)
(24, 25), and culture conditions are detailed in the Supplemental
Data (publishedonTheEndocrine Society’s JournalsOnlineweb
site at http://jcem.endojournals.org).
Tissue samples
Tumors and normal thyroid (NT) tissue samples for immu-
nohistochemical analysis were retrieved from the files of the Pa-
thologyDepartment of theHospital Central deAsturias (Oviedo
University, Asturias, Spain) and of the Hospital Clinico Univer-
sitario de Santiago deCompostela (Santiago deCompostelaUni-
versity, Galicia, Spain). Tumors andNT tissue samples for RNA
extractionandquantitativeRT-PCRwere retrieved fromthe files
of the Department of Surgery, University of Pisa (Pisa, Italy).
Case selection was based on the histological findings and on the
availability of adequate material for RNA extraction. All histo-
logical diagnoses were reviewed by two blinded pathologists
(G.G.-R. and C.D.) according to the latest recommendations
about diagnostic features of PTC, PDC, and ATC (26–28). PDC
were defined as malignant tumors of follicular cells displaying
predominant solid/trabecular/insular growth patterns, high-
grade features such asmitoses (more than three to fivemitoses
10 high power field) and/or necrosis and convoluted nuclei, with
or without concurrent differentiated components of the follicu-
lar or papillary type. ATC were defined as tumors displaying
admixtures of spindle, pleomorphic giant, and epithelioid cells;
high mitotic activity; extensive coagulative necrosis with irreg-
ular borders; and infiltration of vascular walls often accompa-
nied by obliteration of the vascular lumina. After microscopic
examinationof exhaustively sampled specimens, 32 tumorswere
classified as PTC, 93 as PDC, and 56 as ATC. Processing of
samples and of patient information proceeded in agreementwith
review board-approved protocols.
Immunohistochemistry
Formalin-fixed and paraffin-embedded 3- to 5-m-thick tu-
mor sections were deparaffinized, placed in a solution of abso-
lute methanol and 0.3% hydrogen peroxide for 30 min, and
treated with blocking serum for 20 min. The slides were incu-
bated with mouse monoclonal antibodies against TWIST1 (sc-
81417; Santa Cruz Biotechnology, Santa Cruz, CA) and pro-
cessed according to standard procedures. Negative controls by
omitting the primary antibody were included in the assay. Cases
were scored as positive when unequivocal brown staining was
observed in the nuclei of tumor cells. Immunoreactivity was ex-
pressed as the percentage of positively stained target cells in four
intensity categories (, no staining; , low/weak; , moder-
ate/distinct; , high/ intense). Twist1 score values were in-
dependently assigned by two blinded investigators (G.G.-R. and
C.D.), and a consensus was reached on all scores used for
computation.
RNA extraction and expression studies
Total RNA was isolated with the RNeasy Kit (QIAGEN,
Crawley, West Sussex, UK). The quality of the RNAs was ver-
ified by the 2100 Bioanalyzer (Agilent Technologies, Wald-
bronn, Germany); only samples with an RNA integrity number
value above 7were used for further analysis. Real-time PCRwas
performed as detailed in the Supplemental Data: for the calcu-
lation of expression fold changes, sample 1 represented each
single tumor sample, and sample 2was the average of all (n22)
NTs.Microarraymethods are also reported in the Supplemental
Data.
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Protein studies
Immunoblotting was carried out according to standard pro-
cedures. Anti-TWIST1 (sc-81417) and anti-p53 (Pab 240)
monoclonal antibodies were from Santa Cruz Biotechnology;
monoclonal anti--tubulin antibody was from Sigma-Aldrich;
anti-cleaved (Asp175) caspase-3 p17 and p19 fragments poly-
clonal (5A1) antibody was from Cell Signaling Technology, Inc.
(Beverly, MA). Secondary antimouse and antirabbit antibodies
coupled to horseradish peroxidase were from Santa Cruz
Biotechnology.
RNA silencing
Small inhibitor duplex RNA targeting TWIST1 (no. 3, 5, and
7) and the scrambled control [nonspecific small interfering RNA
(siRNA) duplex containing the same nucleotides but in irregular
sequence] have been described previously (16) and were chem-
ically synthesized by Sigma-Aldrich. Based on its higher silencing
efficiency, TWIST1 siRNA 3 (hereafter referred to as TWIST1
siRNA) was selected and used throughout the paper. The day of
transfection, 1105 cellswere incubatedwith50nMsiRNAand
electroporated usingMicroPorator (MP-100, Digital Bio; Euro-
clone,Milan, Italy) according to themanufacturer’s instructions.
Cellswere harvested24, 48, and72hafter transfection, counted,
and analyzed for protein expression.Methods used to determine
cell viability, motility, and invasion are detailed in the Supple-
mental Data.
TWIST1 transfection
The pcDNA 3-TWIST1 vector is described elsewhere (29).
TPC-1 cellswere transfectedbyusing theLipofectamineReagent
(Invitrogen, Carlsbad, CA) according to the instructions of the
manufacturer. Two days later, G418 (Invitrogen) was added at
a concentration of 1.2 mg/ml. Two mass populations of several
clones and three independent cell clones were isolated, ex-
panded, and screened for TWIST1 expression by Western blot
and RT-PCR analysis. One mass population and two cell clones
transfectedwith the control pcDNA3 vectorwere expanded. To
generate stable shRNA (short hairpin RNA)-expressing cell line,
CAL62 cells were transfected with shTWIST1 and shLUC vec-
tors (20) by using the Lipofectamine reagent (Invitrogen) ac-
cording to the instructions of the manufacturer. Two days later,
puromycin (Invitrogen) was added at a concentration of 0.5 mg/
ml. Mass populations and several cell clones were isolated, ex-
panded, and screened for TWIST1 knockdown byWestern blot
and RT-PCR analysis. Methods used to determine cell viability,
motility, and invasion are detailed in the Supplemental Data.
Statistical analysis
Statistical analyses were carried out using the GraphPad In-
Stat softwareprogram(version3.06.3;GraphPadSoftware, Inc.,
San Diego, CA). All P values were two-sided, and differences
were significant when P  0.05.
Results
Up-regulation of TWIST1 in ATC
We evaluated TWIST1 expression levels by immuno-
histochemistry in 157 human tissues including: 15NT, 13
PTC, 88 PDC, and 41 ATC samples. Representative im-
munohistochemical staining is shown in Fig. 1A, and the
entire dataset is reported inTable 1.TWIST1was virtually
undetectable in NT, PTC, and PDC samples. In contrast,
49% of the ATC samples (20 of 41) were positive for
TWIST1 expression. Positivity ranged between at least 5
and nomore than 25% () to at least 60% () of cells
(Fig. 1A and Table 1); no staining was observed in the
absence of the primary antibody (data not shown).
TWIST1 positivity correlated with moderate/high prolif-
eration rate assessed by Ki67/MIB1 immunoreactivity
(Freeman-Haltonextensionof theFisher exactprobability
test, P 0.048) (Supplemental Table 1). There was also a
trend for a significant association with up-regulation of
the cell cycle regulated minichromosome maintenance 5
protein (Freeman-Halton extension of the Fisher exact
probability test, P  0.11) (data not shown). TWIST1
expression correlated with the fusocellular ATC pheno-
type and inversely correlated with the epithelioid ATC
phenotype (2 test, P  0.0002; Freeman-Halton exten-
sion of the Fisher exact probability test, P 0.0001) (Sup-
plemental Table 1), suggesting that TWIST1 is involved in
mesenchymal transition of ATC cells. Accordingly, there
was a trend toward a correlation between TWIST1 up-
regulation and lack of -catenin staining at the plasma
membrane (Freeman-Halton extension of the Fisher exact
probability test, P  0.119) (data not shown). Finally,
TWIST1 positivity correlated with p53 positivity (Free-
man-Halton extension of the Fisher exact probability test,
P  0.030) (Supplemental Table 1).
To determine whether TWIST1 up-regulation also oc-
curred at the RNA level, we examined an independent set
of ATC (n 15), PDC (n 4), PTC (n 19), andNT (n
22) samples byquantitativeRT-PCR.As shown inFig. 1B,
TWIST1 mRNAwas up-regulated by more than 5-fold in
about 50% (seven of 15) of the ATC samples, with values
greater than10-fold in13%(twoof15)of them.NT,PTC,
and PDC samples expressed lower TWIST1 levels com-
pared with ATC (P  0.001) (Fig. 1B).
In vertebrates, there are two TWIST genes, TWIST1 and
TWIST2 (also known as Dermo1), and their encoded pro-
teins showan identity in thebasichelix-loop-helixdomainof
more than 90% (20). Therefore, we alsomeasured TWIST2
expression by quantitative RT-PCR in thyroid tissue
samples. TWIST2 was overexpressed in some cases, but
at a lower extentwith respect to TWIST1 (Supplemental
Fig. 1). Indeed, TWIST2was up-regulated bymore than
2-fold in only about half of the ATC samples (four of
nine), with values greater than 5-fold in only one of nine
ATC samples. No PTC sample up-regulated TWIST2
(Supplemental Fig. 1A).
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Up-regulation of TWIST1 in thyroid cancer cell
lines
We analyzed TWIST1 expression in cultured human
thyroid cells. To this aim, we used primary cultures of NT
follicular cells (P5 4N and S11N) and a panel of PTC
(TPC-1, NIM, BCPAP) and ATC (ACT-1, OCUT-2,
8505C, SW1736, CAL62) cell lines.Western blot analysis
showedup-regulation of a band at approximately 26 kDa,
which corresponded to the TWIST1 protein only in the
ATC cell lines OCUT-2, 8505C, and CAL62 (Fig. 1C).
TWIST1 expression was lower in the other ATC cells
and in all the PTC cell lines analyzed, whereas it was
undetectable in NT cells (Fig. 1C). RT-PCR analysis
confirmed the Western blot results (data not shown).
Finally, CAL62 and BCPAP also up-regulated TWIST2
mRNA by more than 2-fold with respect to NT cells
(Supplemental Fig. 1B).
To confirm TWIST1 expression in a model cell sys-
tem and to start exploring whether TWIST1 up-regu-
lation correlated with loss of differentiation or with an
aggressive tumor phenotype, we used a panel of rat thy-
roid follicular Fischer rat-derived thyroid follicular cell
TABLE 1. TWIST1 expression in thyroid samples
(n  157)
Tissue
TWIST1 positivity, % of positive samples
(positive/total samples)
NT 0% (0/15)
PTC 0% (0/13)
PDC 0% (0/88)
ATC 49% (20/41)  17% (7/41)
 15% (6/41)
 17% (7/41)
, 5 to 25% of positive cells; , 25 to 60% of positive cells;
, 60% of positive cells.
FIG. 1. Expression of TWIST1 in thyroid tissue samples and in cell lines. A, Immunohistochemical analysis of TWIST1 protein expression in normal
and malignant thyroid tissues. Representative histological sections from NT (20 magnification), classical PTC (CL-PTC; 10 magnification),
follicular variant PTC (FV-PTC; 20 magnification), PDC (4 magnification), and ATC (20 and 4 magnification) stained with a mouse
monoclonal anti-TWIST1 antibody are shown. The NT, CL-PTC, FV-PTC, and PDC sections were negative for TWIST1, whereas the two ATC cases
featured high/intense immunoreactivity levels (, e.g. 60% of cells); in particular, the ATC sample at 20 magnification showed 65% of
positive cells, whereas the ATC at 4 magnification showed 85% of positive cells. B, Quantitative RT-PCR of TWIST1 mRNA in NT (n  22), PTC
(n  19), PDC (n  4) and ATC (n  15) snap-frozen tissue samples. The level of TWIST1 expression in each sample was measured by comparing
its fluorescence threshold with the average fluorescence threshold of the NT samples. The average results of triplicate samples are plotted. C, NT
follicular cells (P5 4N and S11N), PTC (TPC-1, NIM, and BCPAP), and ATC (ACT- 1, OCUT-2, 8505C, SW1736, and CAL62) cell lines were analyzed
by immunoblot using a mouse monoclonal anti-TWIST1 antibody. Anti -tubulin monoclonal antibody was used as a control for equal protein
loading. D, Immunoblot of TWIST1 expression in rat thyroid PC cells expressing the indicated oncogenes. ***, P  0.001.
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line PC CI 3 (PC) cells adoptively expressing various
oncogenes (PC-RET/PTC1, PC-RET/PTC3, PC-v-HRAS,
PC-TRK-T1, PC-v-RAF, PC-BRAF V600E, PC-E1A,
PC-E1A-v-RAF, and PC-v-MOS). Although the expres-
sion of v-MOS and of the E1A/v-RAF combination en-
abled PC cells to grow in semisolid medium and to in-
duce tumors in athymicmice, the expression of the RET/
PTC1/3,HRAS, TRK,RAF (v-RAF and BRAF) and E1A
oncogenes only caused loss of differentiation without
fostering a tumorigenic phenotype (24, 25). Figure 1D
shows that TWIST1 was only expressed in the PC cells
transformed by v-MOS, and at lower levels by E1A 
v-RAF. Therefore, TWIST1 up-regulation correlated
with malignant phenotype rather than loss of differen-
tiation of rat thyroid cells.
Knockdown of TWIST1 induces apoptosis of ATC
cells
We evaluated the effects of TWIST1 ablation in ATC
cells by RNA interference. We initially tested, byWestern
blot in CAL62 cells, the efficiency of TWIST1 ablation
using three different siRNA (no. 3, 5, and7) (16). TWIST1
FIG. 2. Effects of TWIST1 knockdown in ATC cells. A, CAL62, 8505C, and OCUT-2 cells were transfected with TWIST1 siRNA or with scrambled
siRNA. Cells were harvested at different time points, and protein lysates were subjected to immunoblotting with the indicated antibodies. B,
CAL62, 8505C, and OCUT-2 cells were transfected with TWIST1 siRNA or with scrambled siRNA and counted at different time points. Values
represent the average of triplicate experiments  95% confidence intervals. C, CAL62 and 8505C cells were transfected with TWIST1 siRNA or
with scrambled siRNA. Cells were harvested at different time points, and protein lysates were subjected to immunoblotting with the indicated
antibodies. D, The indicated cell lines were transfected with TWIST1 siRNA or scrambled siRNA; after 48 and 72 h, cells were collected by
trypsinization, stained for 10 min with trypan blue, and counted in triplicate. The percentage of trypan blue excluding cells compared with cells
transfected with siRNA scrambled is reported  SD. ***, P  0.001.
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siRNA 3 (hereafter named TWIST1 siRNA) reduced
TWIST1 protein levels of about 60% (Fig. 2A) and there-
fore was selected for further experiments, whereas the
other two siRNAs (5 and 7) were less effective, with
siRNA 5 being practically devoid of any effect and siRNA
7 depleting TWIST1 protein by less than 30% (Supple-
mental Fig. 2).
We knocked down TWIST1 by transient siRNA
TWIST1 transfection in CAL62, 8505C, and OCUT-2
cells. As shown in Fig. 2A, a TWIST siRNA silenced the
TWIST1protein starting at 24hafter transfection, and the
effect lasted up to 72 h, whereas a scrambled siRNA con-
trol had no effect (Fig. 2A). Thus, cells were transfected
with TWIST1 siRNA or with scrambled siRNA and
counted at different time points (24, 48, and 72 h) (Fig.
2B). Seventy-two hours after transfection, CAL62 cells
transfected with scrambled siRNA numbered 259 103,
whereas those transfectedwithTWIST1siRNAnumbered
81  103 (P 0.0008); 8505C cells transfected with
scrambled siRNA numbered 679  103, whereas those
transfected with TWIST1 siRNA numbered 351  103
(P  0.0001); OCUT-2 cells transfected with scrambled
siRNA numbered 278  103, and those transfected with
TWIST1 siRNA numbered 176 103 (P
0.0009) (Fig. 2B). It should be noted that
CAL62, but not 8505C and OCUT-2, ex-
pressed detectable levels of TWIST2 (Sup-
plemental Fig. 1B). Thus, it is feasible, be-
cause of the high degree of homology
between TWIST1 and TWIST2, that the ef-
fects of TWIST1 siRNAobserved inCAL62
cells were due to the combined inhibition of
TWIST1 andTWIST2. Accordingly, at 24 h
after siRNA transfection, TWIST2 mRNA
was down-regulated by 1.8-fold in CAL62
(data not shown).
At 48 and 72 h, siRNATWIST1 induced
cell apoptosis of CAL62 and 8505C cells as
measured by immunoblot with an antibody
for the cleaved products of caspase 3 (Fig.
2C). Accordingly, the percentages of trypan
blue excluding (viable) cells, of CAL62
transfected with TWIST1 siRNA 48 and
72h after transfection,were of 69 and32%,
respectively, with respect to scrambled con-
trol, confirming that TWIST1 depletion re-
duced thyroid cancer cell viability (P 
0.001) (Fig. 2D).
Because TWIST1 has been associated
with premature senescence of cancer cells
(20), we performed a senescence-associated
-galactosidase (SA--gal) stainingassayon
siRNA TWIST1-treated cells. Seventy-two
hours after transfection with TWIST1 siRNA, the per-
centage of SA--gal-positive cells was 1.3%, whereas it
was 0.7% in scrambled siRNA transfected cells. As a pos-
itive control, the percentage of SA--gal-positive cells was
38% in normal human diploid fibroblasts treated with
Etoposide (Sigma-Aldrich) (data not shown). Thus, al-
though significant, senescence induced by TWIST1
knockdown involved only a minor fraction of ATC cells.
Knockdown of TWIST1 impairs cell migration and
invasion of ATC cells
Weevaluated themigration (by awound-healing assay)
and invasion (by a Matrigel invasion assay) ability of
TWIST1 siRNA-transfected cells compared with scram-
bled siRNA-transfected cells. As shown in Fig. 3A, 8505C
and OCUT-2 cells transfected with the scrambled control
efficiently migrated into the wound; in contrast, cells
transfected with TWIST1 siRNA had a greatly reduced
migrating ability (P  0.001). Furthermore, cells trans-
fected with TWIST1 siRNA had a reduced ability to in-
vade Matrigel compared with control cells (P  0.001)
(Fig. 3B).
FIG. 3. Effects of TWIST1 knockdown on ATC cell migration and invasion. A, Cells were
transfected with TWIST1 siRNA or scrambled siRNA; a scraped wound was introduced,
and cell migration into the wound was monitored at 24 h. B, Wound closure was
measured by calculating pixel densities in the wound area and expressed as percentage
of wound closure of triplicate areas  SD. C, Cells were transfected with TWIST1 siRNA
or scrambled siRNA; after transfection, cells were seeded in the upper chamber of
transwells and incubated for 12 h; the upper surface of the filter was wiped clean, and
cells on the lower surface were stained and counted. Invasive ability was expressed as
number of invaded cells. Values represent the average of triplicate experiments  SD.
***, P  0.001.
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Effects of stable silencing of TWIST1 in CAL62 cells
We stably transfected CAL62 cells with an shTWIST1
plasmid or with shLUC control (20). After antibiotic se-
lection, cells were screened by Western blot for TWIST1
expression. Amass population (mp) (shTWIST1mp)with
a TWIST1 knockdown of approximately 52% was used
for further study (Supplemental Fig. 3A). Consistent with
data obtained upon transient TWIST1 silencing (Fig. 2),
shTWIST1 mp cells showed decreased migration and in-
vasion abilitywith respect to shLUC-transfected cells (P
0.001) (Supplemental Fig. 3, B–D). To address effects of
TWIST1 knockdown on chemosensitivity, cells were
treated with cisplatin (200 or 1000 nM) or staurosporine
(300or 500nM) and counted at 24h.Upon treatmentwith
cisplatin (1000 nM) or staurosporine (300–500 nM),
shTWIST1 mp cells had a decreased viability compared
with control cells (P  0.001) (Supplemental Fig. 3E).
Finally, the number of colonies formed
in semisolid medium (soft agar) was
also reduced by 2-fold compared with
the shLUCmp control (P 0.05) (Sup-
plemental Fig. 3F). Thus, TWIST1 ab-
lation in vitro affected several hall-
marks of malignancy of CAL62 cells,
including anchorage-independent pro-
liferation, survival, and invasion.
Ectopic TWIST1 promotes cell
migration and invasion of PTC
cells
PTC cells, TPC-1, which have low
endogenous levels of TWIST1, were
transfected with a TWIST1-express-
ing plasmid (pcDNA-TWIST1) or
with the empty vector (pcDNA).Mass
populations and cell clones were se-
lected in G418 (1.2 mg/ml). TWIST1
expression was increased (4- to 13-
fold) in all the cell lines transfected
with TWIST1 comparedwith the con-
trols (Fig. 4A). Growth rate was sim-
ilar in TWIST1- and vector-trans-
fected control cell lines (data not
shown). Therefore, we studied cell
migration using thewound closure as-
say. As shown in Fig. 4, B and C, mi-
gration rate was higher in TWIST1-
transfected cells than in control cells
(P  0.05). We next seeded TWIST1-
transfected and control cells into the
top chamber of transwells and evalu-
ated their ability to invade Matrigel.
TPC-1 cells had basal levels of inva-
siveness, and TWIST1 overexpression further increased
this ability by 4- to 6-fold (P  0.001) (Fig. 4D). Thus,
TWIST1 stimulated cell motility and invasion, although
wound closure and Matrigel invasion extent were not
directly proportional to the TWIST1 expression levels
(Fig. 4). These findings suggest that the TWIST1 ex-
pression level is not the only molecular determinant of
thyroid cancer cell invasive phenotype.
Ectopic TWIST1 protects PTC cells from apoptosis
We treated TPC-1 cells transfected with TWIST1 or
control vector with different concentrations of cisplatin
(200, 1000, and 2000 nM) and counted cell number at
24 h. As shown in Fig. 5A, cell viability was higher in
TWIST1-transfected than in control cells upon treat-
ment with the highest drug dose (P  0.05). Moreover,
FIG. 4. Effects of TWIST1 overexpression on TPC-1 cell migration and invasion. A, Expression
levels of TWIST1 in TPC-1-transfected cells. After G418 selection, cells were lysed and blotted
with the indicated antibodies. B, A scraped wound was placed on the confluent monolayer of
TPC-1 transfected with TWIST1 or the empty vector, and the cell migration into the wound
was monitored at 24 h. Arrows indicate the site of wound closure. C, Wound closure was
measured by calculating pixel densities in the wound area and expressed as percentage of
wound closure of triplicate areas  SD. D, Cells were seeded in the upper chamber of
transwells and incubated for 12 h; the upper surface of the filter was wiped clean, and cells
on the lower surface were stained and counted. Invasive ability was expressed as number of
invaded cells. Values represent the average of triplicate experiments  SD. *, P  0.05;
**, P  0.01; and ***, P  0.001.
E778 Salerno et al. TWIST1 in Thyroid Tumor Progression J Clin Endocrinol Metab, May 2011, 96(5):E772–E781
the amount of caspase 3 cleaved product was lower in
TWIST1-transfected than in control cells (Fig. 5B).
Finally, we searched an Affymetrix microarray-based
data set for genes that were previously reported to be
TWIST1 targets and related to cell cycle and apoptosis
control (30). TWIST1-overexpressing cells (TPC-1
TWIST1 mp1, TWIST1 mp2, and TWIST1 Cl2) up-reg-
ulated (P 0.05), with respect to pcDNAmp control, the
expression of AKT2 (average fold change  SD, 2  0.5)
and BCL-2 (average fold change  SD, 1.67  0.2),
whereas they down-regulated the expression of p21CIP/
WAF1 (average fold change  SD, 0.7  0.3). TWIST1
overexpression, instead, did not significantly change the
expression of p14ARF, BAX, and TIMP1 in our system
(data not shown).
Discussion
Thyroid cancer includes tumor types as different as well-
differentiated carcinomas that have a very good prognosis
and undifferentiated carcinomas or ATC that are among
the most aggressive human cancers. As yet, the molecular
players sustaining such different behavior are largely un-
known. Here, we demonstrate that TWIST1 is up-regu-
lated in ATC samples. Overall TWIST1 up-regulation in
ATC is more prominent at the RNA than at the protein
level. It is possible that TWIST1 overexpression is affected
not only at the transcriptional level but also at the post-
transcriptional level. TWIST1 up-regulation was associ-
ated with mitotic index, as determined by Ki67/MIB1.
However, the fact that TWIST1 did not influence cell pro-
liferation in cultured cells suggests that it is not directly
involved in controlling cell proliferation. In ATC samples,
TWIST1 positivity also correlated with markers of mes-
enchymal transition (fusocellular phenotype) and malig-
nancy (p53 positivity); however, correlation with p53 ex-
pression was not demonstrated in cultured thyroid cancer
cells because TWIST1-positive (OCUT-2, 8505C, and
CAL62) and TWIST1-negative (TPC-1, BCPAP, NIM,
ACT-1,SW1736)cellsbothhadeitherhigh (8505C,ACT-1)
or low/undetectable (CAL62, OCUT-2, TPC-1, BCPAP,
NIM, SW1736) p53 expression (Supplemental Fig. 4).
In vitro cellular models confirmed the role of
TWIST1 in determining the ATC phenotype and iden-
tified the ATC features that were sustained by TWIST1
up-regulation. TWIST1 up-regulation did not correlate
with loss of differentiation; indeed, it did not occur in
PC cells that lost differentiation secondary to the
expression of various oncogenes. Rather, TWIST1
overexpression correlated with a malignant phenotype
being present in tumorigenic PC-v-MOS and PC-
E1Av-RAF cells (24). Moreover, TWIST1 expression
was necessary to counteract spontaneous ATC cell ap-
optosis and to sustain the invasive andmotile phenotype
of ATC cells. Accordingly, when overexpressed in PTC
cells, TWIST1 promoted cell migration and protected
cells from apoptosis. Given the high homology between
TWIST1 and -2, the TWIST siRNA also targeted
TWIST2 (1.8-fold), albeit at lower levels than TWIST1
(2.5-fold). Thus, it is possible that at least in CAL62
cells effects were due to the combined inhibition of
TWIST1 and TWIST2.
TWIST1 expression is responsive to Wnt-1 (31),
IGF-I (32), and nuclear factor B (NF-B) signaling
(33). Elements of the Wnt pathway, particularly
CTNNB1 (the gene coding -catenin), were found to be
mutated in PDC and ATC (34). Moreover, NF-B is ac-
tivated in human thyroid cancer cells, in particular inATC
(35). Therefore, both the Wnt-1/-catenin and NF-B
pathways are good candidates as mediators of TWIST1
up-regulation in ATC.
Up-regulation of TWIST1 is associated with cellular
resistance to anticancer drugs such as cisplatin, taxol, and
vincristine in various types of cancers (18, 19, 36). Here,
we show that TWIST1 overexpression protected thyroid
FIG. 5. Effects of TWIST1 overexpression on TPC-1 cell apoptosis. A,
The cells were treated with increasing doses of cisplatin and counted
24 h after treatment. Data are shown as percentage of inhibition of
cell viability. Values represent the average of three independent
experiments  SD. *, P  0.05; **, P  0.01; and ***, P  0.001. B,
The indicated cell lines were treated with increasing doses of cisplatin,
lysed, and blotted with the indicated antibodies.
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cancer cells from cell death induced by cisplatin and stau-
rosporine. This suggests that TWIST1may be exploited as
a molecular marker of the response of thyroid cancer to
chemotherapy.
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